On the upside
Celgene (Nasdaq: CELG) reported positive results from a Phase III trial of its pancreatic cancer treatment Abraxane.
Annaly Capital Management (NYSE: NLY) offered approximately $839 million to acquire the remaining shares of CreXus Investment (NYSE: CXS) that it does not already own. On the downside
PropThink wrote that the management team at Galena Biopharma (Nasdaq: GALE) was incompetent and that the biotechnology company reported inaccurate clinical trial results.
Beazer Homes (NYSE: BZH) widened fourth quarter losses more than expected even as revenue climbed.
Credit Suisse downgraded J.C. Penney (NYSE: JCP) to an Underperform rating after the department store operator reported wider than expected third quarter losses on Friday.
In the broad market, advancing issues were on par with decliners on the NYSE while advancers barely edged out decliners by a slim margin on Nasdaq. The Russell 2000 which tracks small cap stocks held steady at 795.